Fonte: European Journal of Neuroscience. Unidades: FMRP, FORP
Assuntos: DOENÇA DE PARKINSON, AZUL DE METILENO, ÓXIDO NÍTRICO
ABNT
SANTOS, Keila Dayane Bariotto dos et al. Repurposing an established drug: an emerging role for methylene blue in L‐DOPA‐induced dyskinesia. European Journal of Neuroscience, v. 49, n. 6, p. 869–882, 2019Tradução . . Disponível em: https://doi.org/10.1111/ejn.14079. Acesso em: 18 jul. 2024.APA
Santos, K. D. B. dos, Padovan‐Neto, F. E., Bortolanza, M., Pereira, M. dos S., Raisman-Vozari, R., Tumas, V., & Del Bel, E. A. (2019). Repurposing an established drug: an emerging role for methylene blue in L‐DOPA‐induced dyskinesia. European Journal of Neuroscience, 49( 6), 869–882. doi:10.1111/ejn.14079NLM
Santos KDB dos, Padovan‐Neto FE, Bortolanza M, Pereira M dos S, Raisman-Vozari R, Tumas V, Del Bel EA. Repurposing an established drug: an emerging role for methylene blue in L‐DOPA‐induced dyskinesia [Internet]. European Journal of Neuroscience. 2019 ; 49( 6): 869–882.[citado 2024 jul. 18 ] Available from: https://doi.org/10.1111/ejn.14079Vancouver
Santos KDB dos, Padovan‐Neto FE, Bortolanza M, Pereira M dos S, Raisman-Vozari R, Tumas V, Del Bel EA. Repurposing an established drug: an emerging role for methylene blue in L‐DOPA‐induced dyskinesia [Internet]. European Journal of Neuroscience. 2019 ; 49( 6): 869–882.[citado 2024 jul. 18 ] Available from: https://doi.org/10.1111/ejn.14079